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Bluetongue (BT) is a non-contagious, infectious, arthropod transmitted viral disease of domestic and wild ruminants
that is caused by the bluetongue virus (BTV), the prototype member of the Orbivirus genus in the family Reoviridae.
Bluetongue was first described in South Africa, where it has probably been endemic in wild ruminants since antiquity.
Since its discovery BT has had a major impact on sheep breeders in the country and has therefore been a key focus of
research at the Onderstepoort Veterinary Research Institute in Pretoria, South Africa. Several key discoveries were made
at this Institute, including the demonstration that the aetiological agent of BT was a dsRNA virus that is transmitted by
Culicoides midges and that multiple BTV serotypes circulate in nature. It is currently recognized that BT is endemic
throughout most of South Africa and 22 of the 26 known serotypes have been detected in the region. Multiple
serotypes circulate each vector season with the occurrence of different serotypes depending largely on herd-immunity.
Indigenous sheep breeds, cattle and wild ruminants are frequently infected but rarely demonstrate clinical signs,
whereas improved European sheep breeds are most susceptible. The immunization of susceptible sheep remains the
most effective and practical control measure against BT. In order to protect sheep against multiple circulating
serotypes, three pentavalent attenuated vaccines have been developed. Despite the proven efficacy of these vaccines
in protecting sheep against the disease, several disadvantages are associated with their use in the field.
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Bluetongue (BT) is a non-contagious, infectious, arthro-
pod transmitted viral disease of ruminant and camelid
species which is caused by the bluetongue virus (BTV),
the prototype member of the Orbivirus genus in the family
Reoviridae [1]. Bluetongue virus contains ten linear
dsRNA genome segments [2], that encode seven structural
(VP1-VP7) and 5 non-structural proteins (NS1, NS2, NS3,
NS3/A, NS4) [3,4]. Variation in the outer capsid proteins,
especially VP2, determines serotype specificity [5] and 26
serotypes of the virus have been identified [6]. These sero-
types exist in a complex network of serological cross rela-
tionships, varying from partial to no protection between
heterologous strains [7]. Except for serotype diversity, the* Correspondence: peter.coetzee@yahoo.com
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reproduction in any medium, provided the orlocalized circulation of the virus in different ecosystems
throughout the world has also led to the evolution of dis-
tinct geographical variants or topotypes of the virus. Blue-
tongue viruses are broadly divided into western and
eastern lineages and further regional topotypes, based on
phylogenetic analysis of nucleotide sequences from the
majority of the genome segments. Viruses from the
western lineages circulate in Africa, the Caribbean and the
Americas, whereas those from eastern lineages are
endemic in Asia, Indonesia and Australia [8,9]. The classi-
fication of BTV is complicated by the virus’s ability to
reassort and/or recombine its genome segments in host or
vector cells that have concurrently been infected with
more than one strain or serotype of the virus [10-13]. It is
possible that novel strains may arise in nature of which
the genome segments (or portions of the genome seg-
ments) are not all derived from one parental virus [13-15].
It is therefore desirable that viral topotyping be conducted
through the analysis of sequence data from more than a
single genome segment.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adult female haematophagous midges that belong to the
Culicoides genus [16]. Over 1400 species have been
described, but only 30 or so have been implicated in the
transmission of the virus [17]. The distribution of BT is
closely linked to the distribution of vector competent
midge species and climatic conditions that support a
large population of the insects. Bluetongue is therefore
endemic primarily in the tropical and sub-tropical
regions between the latitudes of 40 °N and 35 °S,
although in certain regions of North America and China
the disease has been detected up to 50 °N [18]. Since
1998 there has been a dramatic change in the distribu-
tion of BT, with the disease having spread into countries
of north-western Europe and Scandinavia [19,20]. There
is a perception that the northward expansion and per-
sistence of bluetongue in regions of Europe that were
previously thought to be beyond the northernmost lati-
tude where climatic conditions could sustain bluetongue,
is partially attributable to the effects of global climate
change [21]. Furthermore novel Palaeartic vectors (par-
ticularly the obsoletus and pulicaris species complexes)
were involved in the transmission of bluetongue in
northern Europe [17]. Due to the wide distribution of
these midge species in the Palearctic region, the whole
of Europe is considered to be continued risk of BT out-
breaks and it can be expected that the introduction of
new BTV strains and serotypes will continue to occur on
a regular basis [22].
Bluetongue virus can infect most ruminant and cam-
elid species but severe disease is usually only seen errat-
ically in certain breeds of sheep (especially in European
fine wool and mutton breeds) and some species of wild
ruminants such as North American white tailed deer
[23,24]. Cattle and goats are usually sub-clinically
affected [23], although acute infections may occur when
the virus spreads into immunologically naive populations
in regions where it is not normally encountered. For
example during the recent outbreak of BTV-8 in Europe,
clinical disease was noted in both cattle and goats.
Clinical signs documented in cattle included ocular dis-
charge, conjunctivitis, oral mucosal congestion, develop-
ment of ulcers and necrotic lesions on the lips and
tongue as well as oedema [25], whereas goats demon-
strated an acute drop in milk production, oedema of the
lips and head, nasal discharge and erythema of the skin
and udder [26]. Nevertheless in endemic regions cattle
(and goats) are commonly considered to be amplifying
hosts of BTV, due to a prolonged viraemia that usually
occurs in the absence of clinical signs [27]. Other routes
of transmission of BTV include venereal transmission
through virus contaminated semen during the period of
infectious viraemia [28] as well as direct contact trans-
mission through the oral ingestion of contaminatedplacental or foetal material [29]. Infection of pregnant
sheep and cattle with certain strains of the virus, espe-
cially attenuated vaccine strains (MLVs), may also lead
to transplacental infection. Depending on the time of
gestation when the foetus is infected, transplacental in-
fection may result in either still births, abortions, or the
birth of non-viable offspring with severe central nervous
system deformities [30,31]. Notably the BTV-8 strain
that recently spread throughout much of Europe demon-
strated the capability to cross the placenta of ruminants
to cause foetal infections at a high frequency, a property
that had not previously been generally associated with a
wild type strains of the virus [29,32,33]
Bluetongue virus preferentially infects endothelial cells
lining the walls of blood vessels, as well mononuclear
phagocytic and dendritic cells [34-36]. Virus-mediated
damage to endothelial cells results in vascular throm-
bosis, tissue infarction, necrosis and haemorrhage
[23,35,37,38]. These lesions manifest clinically in sheep
as fever, serous to bloody nasal discharge, severe pul-
monary and facial oedema, oral erosions and ulcers,
lameness with hyperaemia of the coronary band and tor-
ticollis [23,38]. The clinical presentation of BT can also
vary widely amongst susceptible sheep and can range
from sub-clinical infections in the majority of cases to
severe disease and death of infected animals. The mor-
tality among susceptible sheep ranges from 2-30% [38]
but can occasionally be as high as 70% [39]. Animals
that recover from the disease typically demonstrate a
protracted recovery period, during which they may show
wasting and a reduction in fertility, milk production and
the quality of wool [23,38].
The economic losses that are associated with BT can
be substantial. It is estimated for example that world-
wide economic losses associated with BT in 1996
exceeded 3 billion US dollars [40]. Except for direct eco-
nomic losses that are caused by high morbidity and mor-
tality, BT also causes significant losses due to imposition
of trade restrictions on ruminants and their germ plasm
from BT affected regions [41]. Other indirect losses
include the costs that are associated with surveillance
and mass vaccination, vector control and the treatment
of clinically affected animals [42].
History of bluetongue research in South Africa
Bluetongue has been known in Africa for over a hun-
dred years and has probably been endemic in wild
ruminants in sub-Saharan Africa since antiquity [38].
The first official report of BT emanated from the Cape
Province of South Africa in the late eighteenth
century, following the importation of susceptible Mer-
ino sheep from Europe. The disease was initially called
“fever” or “epizootic catarrh”, but was later referred to
as “malarial catarrhal fever of sheep”, due to the
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intracorpuscular parasite [43,44]. The disease was later
renamed “bluetongue” (1905), with reference to the
characteristic cyanotic tongues that were occasionally
observed in infected sheep [45].
Bluetongue has been an important disease of sheep in
southern Africa ever since its discovery and has there-
fore been a major focus of research at the Onderstepoort
Veterinary Institute (OVI) in Pretoria, South Africa.
Several key discoveries with regards to the nature of the
aetiological agent and its epidemiology were made at the
Institute [46]. In 1905, Sir Arnold Theiler demonstrated
that the aetiological agent of BT could be passed through
a filter, thus indicating that the disease was caused by a
virus [47]. Theiler also introduced the first vaccine against
BT that consisted of a single virus strain (BTV-4) that
was attenuated by serial passage in sheep. This crude
blood vaccine induced remarkable cross-protection to
other serotypes and was used by sheep farmers in South
Africa for over 40 years [48,49].
Based on circumstantial evidence such as a strong sea-
sonal incidence and the fact that sheep could be pro-
tected by stabling at night and by avoiding low lying
pastures, it was surmised that an insect vector was re-
sponsible for the transmission of BTV. The development
of light traps at the OVI for capture of large numbers of
Culicoides at night enabled Du Toit (1944) to demon-
strate that BT could be induced in susceptible sheep
that were inoculated with suspensions of wild caught
Culicoides imicola. Du Toit subsequently confirmed that
Culicoides spp. were biological vectors of BTV, when
he demonstrated that C. imicola which had been fed
on BTV infected sheep, could transmit the disease
to healthy sheep after an extrinsic incubation period of
several days in the insects [16].
Frequent failures of the vaccine that was prepared
from the Theiler strain led Neitz in 1948 to investigate
the plurality of BTV strains in nature by cross-protection
studies in sheep. This work confirmed that sheep that
had been infected with a particular strain developed life-
long protective immunity against re-infection with the
same strain, but only partial to no protection against
infection with heterologous field strains [50]. These
findings led to the first studies on the serotyping of
BTV field isolates, an essential step that was instru-
mental in the development of effective cross-protective
vaccines against multiple circulating BTV serotypes.
Howell and colleagues developed an in vitro serum virus
neutralization test in the 1960s that they used to classify
22 southern African field isolates into 12 serotypes [51],
a number which was expanded by an additional 4 sero-
types by plaque inhibition assay in the 1970s [52]. The
development of serotyping assays placed the OVI in a
position to assist other countries with the serotypingof their viruses. In 1963 the World Organisation for
Animal Health (OIE) designated the OVI as an OIE
reference centre for BT, a function that it currently still
performs [46].
The demonstration of the antigenic diversity of BTV
field isolates combined with the successful adaptation
and propagation of BTV in fertile hen’s eggs and later
cell culture, led to the development of effective multiva-
lent cross-protective vaccines that supplanted the old
Theiler vaccine. In the mid 1940s a lyophilized chicken
embryo-propagated quadrivalent attenuated vaccine had
been developed, which was highly effective in protecting
sheep against BT [53]. This vaccine was later replaced
with 3 cell culture adapted pentavalent vaccines each
consisting of 5 serotypes, that are still used to vaccinate
sheep in southern Africa today [49].
The development of in vivo and in vitro systems for
the large scale propagation of BTV in the 1940s paved
the way for physiochemical, antigenic and genetic stud-
ies of the virus as well as the development of diagnostic
assays. These studies indicated that BTV was a dsRNA
virus that contained ten linear genome segments [2]
enclosed within a triple layered protein capsid [54],
eventually leading to its classification into a newly cre-
ated Orbivirus genus [55]. The cloning of the genome
segments of 21 southern African serotypes in the 1970s-
1980s also led to the development of cross-hybridization
assays which could be used to detect and type BTV field
isolates. These studies identified segment 5 (encodes
NS1) as the most appropriate segment for the diagnosis
of BTV, whereas segment 2 (encodes VP2) was identified
as being suitable for serotyping of field isolates [56].
Global recognition of bluetongue
In the 1940s it was thought that BT was confined to
southern Africa and that outbreaks of the disease in
other regions of the world reflected the emergence of
the virus from the African continent [18]. This assump-
tion was soon challenged by the recognition of the dis-
ease in geographically widespread regions outside Africa.
The first recognized outbreak of BT outside Africa
occurred in Cyprus in 1943 [39]. Bluetongue virus was
thereafter recognized as the causative agent of “sore
muzzle” in sheep in California in 1952 [57] and in 1956–
1957 a severe outbreak of BT that killed approximately
180 000 sheep occurred in the Iberian Peninsula [58]. It
was initially thought that Australia was free from BT;
however BTV-20 was isolated from Culicoides from the
Northern Territory of the country in 1976 [59]. Blue-
tongue has subsequently been isolated from many
regions in Africa, the Americas, the Middle East, the
Indian subcontinent, China, south East Asia, northern
Australia and Europe and it is thought that only
Antarctica is currently free of BTV infection [23].
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Peninsula in the mid 1950s highlighted the threat which
the disease could potentially pose to the supposedly BT
free nations of Europe and Australia. The World Organ-
isation for Animal Health (OIE) therefore classified BT
as a list “A” disease in the mid 1960s. This decision for
many years justified the imposition of strict import and
export regulations on animals and their germ plasm
from BT affected regions. Paradoxically the imposition
of these regulatory measures had a more severe eco-
nomic impact on BT affected countries and the global
livestock industry than the disease itself [18]. With the
recent spread of the disease into previously unaffected
regions of northern Europe (including Scandinavia) and
the incursion of several additional serotypes into south-
eastern regions of the United States and northern
Australia [21,60], BT has again risen in prominence as
one of the important agricultural diseases of the 21st
century.
Bluetongue in South Africa
Bluetongue is commonly seen in South Africa in late
summer and autumn (between February to April), espe-
cially in areas with high rainfall and after good rains.
In colder regions such as the southern Free State, the
disease usually disappears with the occurrence of the
first winter frosts, while it is probable that in warmer
regions such as the KwaZulu Natal and Limpopo pro-
vinces the disease may be transmitted throughout the
year. It has been suggested that the occurrence of BT in
sheep in late summer and autumn in the country reflects
the build-up of BTV in vector competent midge species
during spring and early summer. A primary infection
cycle may involve either wild antelope or cattle with
sheep subsequently becoming infected as a result of
“spill over” in a secondary infection cycle [38,61].
Bluetongue is a notifiable disease in terms of the South
African Animal Diseases Act of 1984. Adherence to the
act is however poor and outbreaks are not always
reported. Only wet seasons with a large number of out-
breaks serve to raise any level of concern. No routine
surveillance for BT is carried out and information
regarding serotype prevalence is based on the retrospect-
ive analysis of samples that are sporadically submitted to
the OVI, as well as a limited number of field surveys.
These surveys have indicated that 22 of the known 26
serotypes are present in South Africa, with serotypes 20,
21, 25 and 26 being considered to be exotic. An analysis
of 258 ovine samples that were submitted to the OVI be-
tween 1983 and 2003 from all provinces of South Africa
indicated that low denomination serotypes (1–4) were
isolated most frequently and that some serotypes were
extremely rare not having occurred for a period of more
than 20 years (18, 19, 22, and 23). However, the analysisof these samples also indicated the presence of serotype
17, which had up till then not been detected in the
country [62]. A single molecular epidemiological study
using the NS3/A gene of BTV has been conducted in
South Africa [63]. In this study different serotypes that
were collected from widespread regions throughout the
country were analyzed. The phylogeny that was inferred
from the nucleotide sequence data of the NS3/A gene
indicated that BTVs in South Africa cluster into two dis-
tinct lineages irrespective of their serotype, geographic
area and year of isolation, suggesting that the transmis-
sion of these lineages is not restricted to any particular
vector species or area of the country. Interestingly BTV
isolates from the United States clustered into both
lineages, supporting the notion that more than one
introduction of BTV from southern Africa may have oc-
curred into the United States in the past.
In South Africa multiple serotypes circulate each vec-
tor season however the occurrence of different serotypes
is unpredictable and is most likely influenced by herd
immunity. Monitoring of Culicoides spp. between 1978
and 1985 at various sites throughout South Africa indi-
cated that 14 to 18 different serotypes were encountered
every season, although at varying frequencies [64].
Usually three to five serotypes were isolated predomin-
antly. These serotypes were replaced with other domin-
ant serotypes the following season, just to become
dominant again three to four years later. Serotypes
which were most commonly encountered included 1–6,
8, 11 and 24. Serotypes 9, 10, 12, 13, 16 and 19 were
encountered every season but at a much lower fre-
quency, while serotypes 7, 15 and 18 were encountered
only sporadically. Serotypes 1–6, 8, 11 and 24 are
believed to have a high epidemic potential, whereas sero-
types 1–6 and 10 which are more often associated with
clinical disease in sheep are thought to have a high
pathogenic index [38,49].
Bluetongue virus has been isolated from many differ-
ent Culicoides species in South Africa, however only two
species, Culicoides imicola and Culicoides bolitinos, are
recognized as significant in the transmission of BTV.
Culicoides imicola, whose larvae primarily inhabit organ-
ically enriched soils, is the dominant vector of BT in
regions throughout South Africa [65]. Culicoides boliti-
nos is almost as widespread as C. imicola, but is domin-
ant in the cooler regions of the country. This species,
which breeds primarily in the dung of domestic and wild
herbivores [66], has been shown to be significantly more
susceptible to oral infection with BTV than C. imicola
[65,67,68]. Bluetongue virus has also occasionally been
isolated from mosquitoes that may play a role in the
mechanical transmission of the virus [62].
The susceptibility of wild ruminants to BT in South
Africa was first established by the experimental infection
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a sub-clinical infection with a sufficiently high virus titre
to infect sheep that were experimentally injected with
infected blood [69]. Evidence has subsequently been
obtained that many wild African herbivore species are
susceptible to infection, however these animals do not
develop clinical disease. A survey was undertaken in
1997 in which wild African herbivores were sampled
throughout South Africa from regions with differing
vegetation and rainfall. Of the more than 18 species that
were sampled, 10 tested positive for BTV antibodies.
Species that had the highest sero-prevalences included
the African elephant (Loxodonta africana), blue wilde-
beest (Connochaetes taurinus), black wildebeest (Con-
nochaetes gnou) and buffalo (Syncerus caffer). Other
species that tested positive included Red hartebeest
(Alcelaphus buselaphus), impala (Aepyceros malampus),
eland (Taurotragus oryx), blesbuck, gazelle (Antidorcas
marsupialis) and giraffe (Giraffa camelopardalis) [70].
Following reports of deaths and abortions among
pregnant bitches that were vaccinated with a BTV-11
contaminated commercial modified-live virus vaccine
(canine distemper virus, canine parainfluenza virus,
canine adenovirus-2 and canine parvovirus) [71], a struc-
tured survey of BTV sero-prevalence was conducted
amongst wild and domestic carnivores in regions of
southern and eastern Africa. This study indicated that a
wide range of African carnivores can be infected with
the virus. Species that tested seropositive included
cheetah (Acinonyx jubatus), lions (Panthera leo), African
wild dogs (Lycaon pictus), spotted hyenas (Crocuta cro-
cuta), jackal (Canis spp.), large spotted genets (Genetta
tigrina), domestic dogs (Canis familiaris) and cats (Felis
catus). Antibodies against 12 different serotypes were
identified during the survey, with serotypes 3, 8, 13 and
17 being associated most commonly with the surveyed
carnivore species. Wild carnivores that had the highest
sero-prevalences included large free- ranging species
such as lion, spotted hyenas and African wild dogs,
whereas smaller carnivores such as jackal and cheetah
had lower sero-prevalences. It is assumed that infection
of larger carnivores follow the ingestion of BT infected
carcasses, whereas smaller carnivores that scavenge on
partially decomposed carcasses have correspondingly
lower sero-prevalences [72]. Many questions remain to
be answered with regards to BT infections in African
carnivore species. It is unknown for example what im-
pact BT has on the population structure of endangered
species such as cheetah and African wild dogs and
whether infections of wild and domestic carnivores
play any role in the onward transmission of BT to
domestic ruminants.
The total population of sheep in South Africa is
approximately 28 million that are distributed across all 9provinces of the country. Most indigenous African sheep
breeds do not show clinical signs of BTV infection and
therefore the disease is not considered to be of major
concern in many sheep rearing rural communities in the
country. A large population of susceptible improved
European wool and mutton breeds in which outbreaks of
clinical disease are common, are however commercially
farmed in South Africa [38,62]. From 1998 to 2000 the
number of outbreaks reported per annum amongst sheep
varied from 28 to almost 100, with the majority of out-
breaks occurring during the wettest years [62]. Most
unvaccinated sheep are infected with BTV at an early age
and BTV antibody-negative sheep are therefore not read-
ily found. For example, a sero-prevalence survey for
BTV-specific antibodies was conducted amongst Merino
sheep in the high-lying regions of the Eastern Cape,
where sheep are not vaccinated since BT disease is not
recognized. This survey indicated that a large proportion
of Merino sheep that were bled in early spring and
autumn tested positive for antibodies against the virus.
Sero-prevalences amongst Merino sheep varied on a
monthly basis from 1% to 84% [62]. A second survey was
conducted in the wet, fairly tropical and low lying
regions of KwaZulu Natal. In this survey a primarily
unvaccinated rural/communal population of indigenous
livestock or crosses thereof was targeted. In total 2852
animals were sampled of which a quarter consisted of
sheep and the remainder consisted of goats. BTV anti-
bodies were found in 63.7% of these animals [62].
Cattle typically do not develop clinical signs of BT and
are rarely tested or vaccinated. In 1996 however, during
an exceptionally wet year, BT was reported in cattle from
regions throughout South Africa. Clinical signs included
stomatitis, coronitis, lacrimation, salivation, nose and
teat sloughs and haemorrhagic diarrhoea. The morbidity
and mortality amongst infected animals were low, but a
marked reduction in milk production was noted [73].
Twenty one BTV and nine epizootic haemorrhagic dis-
ease virus (EHDV) isolates were made from cattle during
that season at the OVI, with co-infection with the two
viruses apparently exacerbating the severity of clinical
signs. The BTV isolates that were responsible for the
outbreak were typed as serotypes 2, 3, 6 and 8, while the
EHDV isolates were identified as serotype 6 [62].
Diagnosis and control of bluetongue in southern Africa
Bluetongue is a well known disease in South Africa and
a presumptive diagnosis is usually based on clinical
signs. Several diseases and conditions may however be
confused with BT in sheep. These include hepatogenous
photosensitivity caused by plant and mycotoxin poison-
ing, foot-and-mouth disease, polyarthritis, foot rot, white
muscle disease, heartwater and pulpy kidney disease.
Clinical BT in cattle may be confused with malignant
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infectious bovine rhinotracheitis and epizootic haemor-
hagic disease [38]. Sheep suffering from bluetongue
are rarely if ever euthanised. Farmers are advised to
enclose affected sheep in small camps where food,
water and shade are close at hand and the animals are
left to recover on their own. Antimicrobial- and anti-
inflammatory drugs are sometimes administered.
In South Africa the ubiquitous distribution of vector
competent midge species and unvaccinated wild and do-
mestic ruminants makes eradication of BT impossible.
Control is therefore targeted to limit the economic
impact of the disease amongst susceptible sheep. Prac-
tical procedures that limit the exposure of sheep to Culi-
coides bites include the avoidance of low-lying wet
pasture, stabling of animals between dusk and dawn,
shearing of sheep in early summer to allow for some
wool growth before the high exposure months in late
summer and autumn and the use of insect repellents
[74]. The control of Culicoides in or around stables may
also have some success in reducing the exposure of
animals to Culicoides bites. The use of larvicides to kill
larvae in soil and the drainage of water pools to reduce
available breeding sites has also been suggested [75].
The most effective and cost effective method of pro-
tecting sheep against multiple circulating serotypes in
South Africa remains the immunization of susceptible
animals. The only vaccine that is widely used in south-
ern Africa is produced by Onderstepoort Biological Pro-
ducts (OBP, Pretoria, South Africa) and consists of field
strains that have been attenuated by serial passage in
embryonated chicken eggs and BHK-21 cell culture. This
vaccine is sold as 3 bottles, each containing 5 serotypes.
Bottle A consists of serotype 1, 4, 6, 12 & 14; bottle B
serotypes 3, 8, 9, 10 & 11 and bottle C serotypes 2, 5, 7,
13 & 19 [49]. Despite the fact that 22 serotypes of BTV
have been isolated in southern Africa, only 15 serotypes
are included in the current vaccine. Types 15, 16, 18 and
22–26 are not included due to their low pathogenicity
for sheep, their low prevalence in Culicoides, or their
relatively recent discovery [38].
The inclusion of specific serotypes in each vaccine bot-
tle was done to prevent interference in the induction of
immunity between the constituent strains due to sero-
logical cross-reactivity. The vaccine bottles are also for-
mulated so that the most attenuated strains (slowest
replicating strains) are applied first, thereby lessening
the potential side effects of less attenuated strains (faster
replicating strains) in the other vaccine preparations. As
vaccine strains are able to replicate in the vaccinated
host (albeit at a reduced rate) they are able to induce
both humoral and cellular immune responses. The de-
velopment of protective immunity is largely based on
the development of serotype-specific neutralizingantibodies that may persist in vaccinated animals for
several years. The vaccine also only demonstrates limited
side effects in sheep in South Africa, which commonly
includes a transient febrile reaction [49].
The individual vaccine bottles are usually applied to
sheep at three week intervals, with immunity to most
serotypes developing within three to four weeks after
administration of the last vaccine bottle. Since immunity
against all vaccine serotypes cannot be guaranteed, it is
recommended that vaccination be repeated on an annual
basis. In southern Africa, sheep are usually vaccinated
with 1 ml of each of the three vaccines from August to
October (spring). Due to the tendency of the cell culture
adapted vaccine strains to cross the ruminant placenta,
it is recommended that ewes be vaccinated 9–12 weeks
before mating. Due to a transitory reduction in semen
quality, rams should be vaccinated after the mating sea-
son. Furthermore the acquisition of colostral immunity
necessitates that lambs be re-vaccinated at 6 months
of age [49]. Although the OBP vaccine has not been
registered for use in cattle, vaccine formulations contain-
ing BTV-2, 4, 9 and 16 have been used in cattle in sev-
eral vaccination campaigns in southern Europe and the
Middle East, with little adverse effects having been
reported [76].
The vaccination of sheep in South Africa is not com-
pulsory and on average only eight million doses of the
vaccine is sold annually. The vaccine provides protection
to approximately one third of the sheep in the country. A
further one million doses is sold to neighbouring coun-
tries each year [49]. Various combinations of attenuated
vaccine strains (3, 2, 4, 8–11, 16) that have been pro-
duced in South Africa, have also been used in the Iberian
Peninsula, the eastern Mediterranean Islands, Italy, Spain,
Portugal, France, Bulgaria and Israel [15,76,77].
Despite strict national and international standards with
regards to manufacturing of the OBP vaccine, several
disadvantages are associated with its use in the field.
Documented side effects in sheep included severe to
mild clinical signs [78], decreased milk production [76],
transplacental infection [29-31], a transient reduction of
semen quality in rams [79] and the suppression of non-
specific lymphocyte blastogenesis when used in goats
[80]. There is also experimental evidence that MLVs may
have an increased potential for secretion in the semen of
older bulls as well as rams [28]. In addition, attenuated
vaccines are not DIVA compliant (able to distinguish
between infected from vaccinated animals) which creates
a problem when conducting surveillance for the disease
[76]. Experimental studies have further demonstrated
that MLVs are able to infect Culicoides and that the vac-
cine strains are able to replicate to a high enough titre in
both the host and vector as to facilitate their onward
transmission in the field [81,82]. Indeed several MLV
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Middle East have been isolated from Culicoides and
sentinel animals. The persistence of MLVs in the field is
of theoretical concern as these strains may possibly be
able to reassort or recombine with other wild type or
vaccine strains to yield novel viruses. These viruses may
potentially display unique biological properties that may
include enhanced virulence or an altered capacity to be
transmitted by Culicoides in the field [14,15]. Further-
more, the prolonged circulation of MLV strains in the
field may also potentially lead to a reversion to virulence
as a result of the accumulation of point mutations (gen-
etic drift) [81].
Research on bluetongue in South Africa
The recent incursion of BTV into the previously un-
affected regions of Europe has again stimulated interest
in BTV research at the larger Onderstepoort complex.
Cross-neutralization studies between the constituent
strains of the live attenuated OBP vaccine in sheep are
currently being conducted, in order to evaluate cross-
protection between the viruses in the ruminant host.
Serological cross-reactivity between different serotypes
in the vaccine was originally evaluated in Guinea pigs,
with little information being available on cross-reactivity
in ruminant species. This work is being done with the
eventual goal of reducing the number of serotypes that
are included in the current OBP vaccine. There is also a
particular interest in determining the immunological
basis for differences in the clinical presentation of BT
between different breeds of sheep, and on indentifying
the genetic markers that influence the virulence and
transmission potential of BTV. Several projects focusing
on epidemiological questions with regards to the sea-
sonal prevalence, overwintering and distribution of BT
in South Africa are also in progress, while research on
the pathogenesis of BTV in economically less important
species such as goats, that may nevertheless play an
important role in the epidemiology of BT, are also being
conducted. Finally the endemicity of BTV in South
Africa as well as the wide availability of vector compe-
tent midge species has made South Africa an attractive
destination for international scientists that are interested
in conducting Culicoides oral susceptibility studies.
Conclusion
Due to the subclinical nature of BT in the majority of
infected sheep, as well as the availability of effective atte-
nuated vaccines, BT is thought to be of less importance
today by veterinary authorities than other livestock dis-
eases that are present in South Africa. Active surveil-
lance for BT is not carried out and the economic impact
which the disease has on the South African livestock in-
dustry is thus difficult to quantify. Nevertheless, not allfarmers choose to vaccinate their animals and outbreaks
of BT amongst unvaccinated sheep continue to occur on
an annual basis. Sheep are exposed to a range of differ-
ent serotypes in each vector season and several serotypes
may be isolated from a single flock of sheep or an indi-
vidual animal. Clinical disease amongst unvaccinated
susceptible sheep in the field can be severe, and it is not
uncommon for sheep farmers in South Africa to suffer
significant losses amongst their flocks as a result of
seasonal outbreaks of BT.
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